Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01571960 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults
A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 4
- Study locations
NCT01571960 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 48 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (89% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT01571960, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will test the safety and immune responses of a prime-boost regimen of two HIV vaccines- a DNA vaccine followed by a modified vaccinia Ankara (MVA) vaccine- in healthy, HIV-uninfected, vaccinia-naive adults.
Conditions Studied
Interventions
- BIOLOGICAL GEO-D03 DNA vaccine
- BIOLOGICAL MVA/HIV62B (MVA62B) vaccine
- BIOLOGICAL Placebo for GEO-D03 DNA
- BIOLOGICAL Placebo for MVA62B:
Study Locations (4)
Alabama
- Alabama CRS - Birmingham
California
- Bridge HIV CRS - San Francisco
Massachusetts
- Brigham and Women's Hospital Vaccine CRS (BWH VCRS) - Boston
New York
- University of Rochester Vaccines to Prevent HIV Infection CRS - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2012-04 |
| Est. Completion | 2016-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01571960
The ClinicalTrials.gov registry entry for NCT01571960 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (89% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 4 interventions - of which GEO-D03 DNA vaccine is the first listed.
NCT01571960 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Alabama, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01571960 about?
NCT01571960 is a clinical study titled "Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults". This study will test the safety and immune responses of a prime-boost regimen of two HIV vaccines- a DNA vaccine followed by a modified vaccinia Ankara (MVA) vaccine- in healthy, HIV-uninfected, vaccinia-naive adults.
What is the current status of trial NCT01571960?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2012-04. Estimated completion is 2016-01.
What conditions does trial NCT01571960 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT01571960?
The interventions under investigation include: GEO-D03 DNA vaccine (BIOLOGICAL), MVA/HIV62B (MVA62B) vaccine (BIOLOGICAL), Placebo for GEO-D03 DNA (BIOLOGICAL), Placebo for MVA62B: (BIOLOGICAL).
Who is sponsoring clinical trial NCT01571960?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01571960 being conducted?
This trial has 4 study locations across Alabama, California, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.